Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
572 participants
INTERVENTIONAL
2004-04-30
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
NCT00206115
Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme
NCT00921362
Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia
NCT00234377
Seroquel XR in the Long Term Treatment of Schizophrenia
NCT01202617
PHARMO Institute Seroquel Safety Study
NCT01342120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Seroquel (quetiapine)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Previous use of atypicals (3 months) or other medications that might influence glucose metabolism
* Contraindications or non-responsiveness for any of the treatments or other safety issues
* Expected non-compliance to treatment and/or study procedures
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca CNS Medical Group
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Burgas, , Bulgaria
Research Site
Rousse, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia- Novi Iskar, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Dobjany, , Czechia
Research Site
Dob¿any U Plzn¿, , Czechia
Research Site
Havlí¿k¿v Brod, , Czechia
Research Site
Kladno, , Czechia
Research Site
Miro¿ov, , Czechia
Research Site
Opava, , Czechia
Research Site
Pilsen, , Czechia
Research Site
Prague, , Czechia
Research Site
Tübingen, Baden-Wurttemberg, Germany
Research Site
München, Bavaria, Germany
Research Site
Bonn, North Rhine-Westphalia, Germany
Research Site
Düsseldorf, North Rhine-Westphalia, Germany
Research Site
Münster, North Rhine-Westphalia, Germany
Research Site
Magdeburg, Saxony-Anhalt, Germany
Research Site
Berlin, , Germany
Research Site
Bonn, , Germany
Research Site
Düsseldorf, , Germany
Research Site
Herten, , Germany
Research Site
Magdeburg, , Germany
Research Site
München, , Germany
Research Site
Tübingen, , Germany
Research Site
Balassagyarmat, , Hungary
Research Site
Budapest, , Hungary
Research Site
Cegléd, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Eger, , Hungary
Research Site
Gy¿r, , Hungary
Research Site
Kaposvár, , Hungary
Research Site
Kecskemét, , Hungary
Research Site
Szeged, , Hungary
Research Site
Szolnok, , Hungary
Research Site
Bergen, , Norway
Research Site
Drammen, , Norway
Research Site
Hagavik, , Norway
Research Site
Stavanger, , Norway
Research Site
Stokmarknes, , Norway
Research Site
Straume, , Norway
Research Site
Tønsberg, , Norway
Research Site
Brasov, , Romania
Research Site
Bucharest, , Romania
Research Site
Iași, , Romania
Research Site
Banská Bystrica, , Slovakia
Research Site
Bojnice, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Domaša, , Slovakia
Research Site
Ko¿ice, , Slovakia
Research Site
Liptovský Mikulá¿, , Slovakia
Research Site
Michalovce Strá¿any, , Slovakia
Research Site
Nitra, , Slovakia
Research Site
Pre¿ov, , Slovakia
Research Site
Rimavská Sobota, , Slovakia
Research Site
¿ilina-Byt¿ica, , Slovakia
Research Site
¿ilina, , Slovakia
Research Site
Medunsa, Pretoria, South Africa
Research Site
Bloemfontein, , South Africa
Research Site
CapeTown, , South Africa
Research Site
Durban, , South Africa
Research Site
Ga-Rankuwa, , South Africa
Research Site
Johannesburg, , South Africa
Research Site
Krugersdorp, , South Africa
Research Site
Parktown, , South Africa
Research Site
Pretoria, , South Africa
Research Site
Tygerberg, , South Africa
Research Site
Sutton Coldfield, West Midlands, United Kingdom
Research Site
Birmingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Leonova-Edlund J, Leong RW, Brecher M. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry. 2009 Apr;70(4):487-99. doi: 10.4088/jcp.08m04132. Epub 2009 Apr 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1441C00125
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.